Free Trial
NASDAQ:TBPH

Theravance Biopharma (TBPH) Stock Price, News & Analysis

Theravance Biopharma logo
$11.52 +0.31 (+2.77%)
Closing price 04:00 PM Eastern
Extended Trading
$11.50 -0.02 (-0.16%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Theravance Biopharma Stock (NASDAQ:TBPH)

Key Stats

Today's Range
$11.20
$11.67
50-Day Range
$10.57
$11.65
52-Week Range
$7.44
$11.88
Volume
586,118 shs
Average Volume
173,276 shs
Market Capitalization
$576 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.33
Consensus Rating
Buy

Company Overview

Theravance Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

TBPH MarketRank™: 

Theravance Biopharma scored higher than 53% of companies evaluated by MarketBeat, and ranked 498th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Theravance Biopharma has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Theravance Biopharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about Theravance Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Theravance Biopharma are expected to grow in the coming year, from ($1.09) to $0.35 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Theravance Biopharma is -9.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Theravance Biopharma is -9.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Theravance Biopharma has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Theravance Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    8.60% of the float of Theravance Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Theravance Biopharma has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Theravance Biopharma has recently decreased by 5.05%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Theravance Biopharma does not currently pay a dividend.

  • Dividend Growth

    Theravance Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.60% of the float of Theravance Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Theravance Biopharma has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Theravance Biopharma has recently decreased by 5.05%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $491,800.00 in company stock.

    • Percentage Held by Insiders

      Only 6.90% of the stock of Theravance Biopharma is held by insiders.

    • Percentage Held by Institutions

      99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Theravance Biopharma's insider trading history.
    Receive TBPH Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

    TBPH Stock News Headlines

    BREAKING: The House just passed 3 pro-crypto bills!
    THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
    TBPH Theravance Biopharma, Inc. - Seeking Alpha
    See More Headlines

    TBPH Stock Analysis - Frequently Asked Questions

    Theravance Biopharma's stock was trading at $9.41 at the start of the year. Since then, TBPH stock has increased by 22.4% and is now trading at $11.52.

    Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.16. The biopharmaceutical company had revenue of $15.39 million for the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative trailing twelve-month return on equity of 32.37%.
    Read the conference call transcript
    .

    Theravance Biopharma's top institutional investors include Geode Capital Management LLC (1.79%), Acadian Asset Management LLC (0.62%), Connor Clark & Lunn Investment Management Ltd. (0.11%) and Campbell & CO Investment Adviser LLC (0.10%). Insiders that own company stock include Richard A Graham and Rhonda Farnum.
    View institutional ownership trends
    .

    Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG).

    Company Calendar

    Last Earnings
    5/08/2025
    Today
    8/08/2025
    Next Earnings (Estimated)
    8/12/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - DRUGS
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:TBPH
    Previous Symbol
    NASDAQ:TBPHV
    CIK
    1583107
    Fax
    N/A
    Employees
    110
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $25.00
    Low Price Target
    $15.00
    Potential Upside/Downside
    +85.4%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.33
    Research Coverage
    3 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($1.18)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$56.42 million
    Net Margins
    -89.38%
    Pretax Margin
    -74.08%
    Return on Equity
    -32.37%
    Return on Assets
    -16.48%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    4.77
    Quick Ratio
    4.77

    Sales & Book Value

    Annual Sales
    $64.38 million
    Price / Sales
    8.93
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $3.57 per share
    Price / Book
    3.22

    Miscellaneous

    Outstanding Shares
    50,000,000
    Free Float
    46,551,000
    Market Cap
    $575.20 million
    Optionable
    Optionable
    Beta
    0.01

    Social Links

    Analysts Agree—These Gold Picks Outshine the Rest Cover

    Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

    Get This Free Report

    This page (NASDAQ:TBPH) was last updated on 8/8/2025 by MarketBeat.com Staff
    From Our Partners